🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-523101-15-00
Completed Phase I

First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)

2025-523101-15-00 · tracked via the Priya Life Science EU tracker
Sponsor
Genmab A/S
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
16/01/2026
Enrollment target
40
Sites
Denmark, Spain

Condition studied

Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523101-15-00 on CTIS ↗ ← All trials in the EU